دورية أكاديمية
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
| العنوان: | Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 |
|---|---|
| المؤلفون: | Haag, G.M., Zoernig, I., Hassel, J.C., Halama, N., Dick, J., Lang, N., Podola, L., Funk, J., Ziegelmeier, C., Juenger, S., Bucur, M., Umansky, L., Falk, C.S., Freitag, A., Karapanagiotou-Schenkel, I., Beckhove, P., Enk, A., Jaeger, D. |
| بيانات النشر: | ELSEVIER SCI LTD |
| سنة النشر: | 2018 |
| المجموعة: | University of Regensburg Publication Server |
| مصطلحات موضوعية: | 610 Medizin, ddc:610 |
| الوصف: | Background: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. Patients and methods: Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks. Primary endpoint was the disease control rate (irCR, irPR or irSD) according to immune-related response criteria (irRC). Secondary endpoints included the disease control rate according to RECIST criteria, progression-free survival and overall survival (OS). Humoural and cellular immune responses against NY-ESO-1 were analysed from blood samples. Results: Disease control rate according to irRC was 52%, irPR was observed in 36% of patients. Progression-free survival according to irRC was 7.8 months, according to RECIST criteria it was 2.9 months. Median OS was 22.7 months; the corresponding 1-year survival rate was 66.8%. Treatment-related grade 3 AEs occurred in 36% with no grade 4-5 AEs. No clear association was found between the presence of NY-ESO-1-specific cellular or humoural immune responses and clinical activity. Conclusion: Ipilimumab demonstrated clinically relevant activity within this biomarker-defined population. NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade. (C) 2017 Elsevier Ltd. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Haag, G.M., Zoernig, I., Hassel, J.C., Halama, N., Dick, J., Lang, N., Podola, L., Funk, J., Ziegelmeier, C., Juenger, S., Bucur, M., Umansky, L., Falk, C.S. , Freitag, A., Karapanagiotou-Schenkel, I., Beckhove, P., Enk, A. und Jaeger, D. (2018) Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. European Journal of Cancer 90, S. 122-129. |
| DOI: | 10.1016/j.ejca.2017.12.001 |
| الإتاحة: | https://doi.org/10.1016/j.ejca.2017.12.001Test https://epub.uni-regensburg.de/47522Test/ |
| رقم الانضمام: | edsbas.7756A8C4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ejca.2017.12.001 |
|---|